Qianyuan Pharmaceutical Releases 2026 Interim Report with Net Profit of 4.2858 Million Yuan

Earnings
โดย Jiemian·CN·Read original
Summary · why it matters

Qianyuan Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 4.2858 million yuan. The company's total operating revenue was 352 million yuan, down 5.66% from the same period last year. Net cash inflow from operating activities was 81.0741 million yuan. The latest asset-liability ratio was 65.53%, gross margin was 66.40%, and ROE was 0.95%.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews